GtoPdb Ligand ID: 6058

Synonyms: AV-951 | AV951 | Fotivda® | KRN-951 | KRN951 | VEGFR tyrosine kinase inhibitor IV
tivozanib is an approved drug (EMA (2017))
Compound class: Synthetic organic
Comment: Tivozanib is an oral VEGF receptor tyrosine kinase inhibitor.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 107.74
Molecular weight 454.1
XLogP 3.53
No. Lipinski's rules broken 0
Canonical SMILES COc1cc2c(ccnc2cc1OC)Oc1ccc(c(c1)Cl)NC(=O)Nc1noc(c1)C
Isomeric SMILES COc1cc2c(ccnc2cc1OC)Oc1ccc(c(c1)Cl)NC(=O)Nc1noc(c1)C
InChI InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
Bioactivity Comments
Tivozanib inhibits all three VEGF receptor tyrosine kinase enzymes with equal potency [3]. The drug formulation contains tivozanib hydrochloride monohydrate (PubChem CID 11547978).
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
kinase insert domain receptor Hs Inhibitor Inhibition 9.8 pIC50 - 3
pIC50 9.8 (IC50 1.6x10-10 M) [3]
fms related receptor tyrosine kinase 1 Hs Inhibitor Inhibition 9.7 pIC50 - 3
pIC50 9.7 (IC50 2.1x10-10 M) [3]
fms related receptor tyrosine kinase 4 Hs Inhibitor Inhibition 9.6 pIC50 - 3
pIC50 9.6 (IC50 2.4x10-10 M) [3]